期刊文献+

血清C反应蛋白、铁蛋白与糖尿病视网膜病变严重程度关系的研究 被引量:7

Serum C-reactive protein,serum ferritin and its relationship with the severity of diabetic retinopathy
在线阅读 下载PDF
导出
摘要 目的探讨血清C反应蛋白(CRP)、血清铁蛋白(SF)水平和糖尿病视网膜病变(DR)严重程度的关系。方法随机选取住院的2型糖尿病患者60例,根据眼底检查结果分为无糖尿病视网膜病变组(NDR)21例、非增值期糖尿病视网膜病变组(NPDR)20例、增值期糖尿病视网膜病变组(PDR)19例。比较3组患者CRP、SF水平的关系。结果 CRP、SF水平在NDR组、NPDR组、PDR组中逐渐升高,3者间比较差异有统计学意义(P<0.05)。多因素有序logistic回归分析显示CRP SF是DR严重程度的独立危险因素。结论血清CRP、SF水平和DR严重程度密切相关,应重视早期监测血清CRP和SF。 Objective To investigate serum C-reactive protein, serum ferritin and its rela- tionship with the severity of diabetic retinopathy. Methods According to the fundus examination, hospitalized patients with type 2 diabetes were randomly chosen and divided into three groups, in- cluding no diabetic retinopathy group (NDR group, n = 21), non-proliferative diabetic retinopathy group (NPDR group, n = 20) and proliferative diabetic ertinopathy group (PDR group, n = 19). The differences in the level of C-reactive protein and serum ferritin were analyzed. Results Total C -reactive protein, serum ferritin in NDR group, NPDR group and PDR group gradually increased, and the differences among three groups were statistically significant (P ~ 0.05). Logistic multivari- ate regression analysis showed that C-reactive protein and serum ferritin were independent risk fac- tors of diabetic retinopathy. Conclusion The levels of C-reactive protein and serum ferritin which have some certain relationship with the severity of diabetic retinopathy should be monitored as early as possible.
作者 蒋燕 缪珩
出处 《实用临床医药杂志》 CAS 2012年第17期150-152,共3页 Journal of Clinical Medicine in Practice
关键词 糖尿病 2型 糖尿病视网膜病变 C反应蛋白 血清铁蛋白 type 2diabetes diabetic retinopathy C-reactive protein serum ferritin
  • 相关文献

参考文献15

二级参考文献174

共引文献122

同被引文献85

  • 1陈雪,石晓聪,曹晓华,等.游离脂肪酸水平92型糖尿病及糖尿病性视网膜病变的关系[J].中外医学研究,2013,11(23):191.
  • 2Wilkinson-Berka JL, Tan G, Jaworski K, et al. Valsartan but not Atenolol improves vascular pathology in diabetic Ren-2 rat retina[l]. Am l Hypertension, 2007, 20(4): 423-430.
  • 3Sultan MB, Zhou D, Loftus J, et al. A phase 2/3, multicenter, randomized, double-masked, 2 -year trial of pegaptanib sodium fbr the treatment of diabetic macular edema[J]. Ophthalmology, 2011, 118(6): 1107-1118.
  • 4Cunningham El', Adamis AP, Altaweel M, et al. A phase ll randomized double-masked trial of pegaptanib,an anti-vascular endothelial growth factor aptamer, tbr diabetic macular edema[J]. Ophthalmology, 2005, 112(10): 1747-1757.
  • 5Ishikawa K,Honda S,Tsukahara Y, et al. Preferable use of intravitreaJ bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy[J]. Eye(Lond, England), 20/)9, 23( 1 ): 108-111.
  • 6Nonaka A, Kiryu J, Tsujikawa A, et al. Inhibitory effect of ischemic preconditioning on leukocyte participation in retinal ischemia-reperfusion injury[J]. Invest Ophthalmol Vis Sci, 2001, 42(10): 2380-2385.
  • 7Aiello LP, Davis MD, Girach A, et al. Effect of Ruboxistaurin on visual loss in patients with diabetic retinopatby[J]. Ophthalmology, 2006, 113(12) : 2221-2230.
  • 8Jonas J, Heatley G, Spaide R, et al. lntravitreal triamcino lone acetonide and secondary ocular hypertension[J]. J Glaucoma, 2005, 14(2): 168-171.
  • 9Massin E Audren F, Haouchine B, et al. lntravitreal triamcinoloneacetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial[J]. Ophthalmology, 2004, 111 (2): 218-224.
  • 10Forouhi NG,Harding AH,A11ison M,et al.Elevated serum ferritin 1evels predict new-onset type 2diabetes:results from the EPIC-Norfolk prospective study[J].Diabetologia,2007,50(5):949-956.

引证文献7

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部